Abeona Therapeutics Inc (NASDAQ:ABEO) Shorts Reduced By 2.22% As Of Dec 8, 2018

Abeona Therapeutics Inc. (NASDAQ:ABEO) Corporate Logo

Change of 2.22% for Abeona Therapeutics Inc (NASDAQ:ABEO)’s shares shorted was noted. It was published in December by FINRA the 11.96M shares shorted on ABEO. The 12.23 million previous shares are down with 2.22%. 27 days will cost ABEO with 439,600 average volume to recover its previous position. 40.81% is Abeona Therapeutics Inc float short.

Ticker’s shares touched $8.54 during the last trading session after 4.79% change.Abeona Therapeutics Inc. has 1.12M shares volume, 71.21% up from normal. ABEO is uptrending and has moved 5.07% since December 8, 2017. ABEO underperformed by 10.55% the S&P 500.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases.The company has $409.45 million market cap. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A.Last it reported negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Total analysts of 3 have positions in Abeona Therapeutics (NASDAQ:ABEO) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since June 27, 2018 according to StockzIntelligence Inc Abeona Therapeutics has 3 analyst reports. The company rating was maintained by Citigroup on Tuesday, November 13.

For more Abeona Therapeutics Inc. (NASDAQ:ABEO) news announced briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Crainscleveland.com or Globenewswire.com. The titles are as follows: “Gene therapy players under pressure – Seeking Alpha” announced on September 05, 2018, “3 Things In Biotech, April 22: All These ‘A’ Companies – Seeking Alpha” on April 23, 2018, “Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback – Seeking Alpha” with a publish date: March 16, 2018, “Abeona Therapeutics fires CEO Carsten Thiel – Crain’s Cleveland Business” and the last “Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA – GlobeNewswire” with publication date: February 08, 2018.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.